#26-01 Correction of NGM Market Notice 25-127 Rights issue in Niutech Group AB

Niutech Group AB's board has resolved a rights issue with preferential rights: record date January 7, 2026; shareholders receive one subscription right per share and twelve rights entitle subscription to eight new shares at SEK 0.25 per share. Subscription runs January 9–23, 2026, trading in subscription rights is January 9–20 and trading in paid subscription shares January 9–February 11 on NGM; the notice corrects listing names/symbols to Niutech Group TR/BTA (ISINs SE0027100801 and SE0027100819) and reports issued instrument counts of 96,329,631 (TR) and 40,137,346 (BTA).

Analysis

MARKET STRUCTURE: The 12-for-8 rights issue (12 rights → 8 new shares at SEK0.25) implies a ~40% incremental dilution of post-issue equity if fully subscribed (new shares = 8/20 of post-cap). Immediate winners are counterparties who can buy rights cheaply and subscribe; losers are non-participating shareholders facing ~40% ownership dilution and likely near-term price pressure around the ex-rights date (ex-rights Jan 5, record Jan 7, rights trade Jan 9–20, BTA trade to Feb 11). Cross-asset impact is limited but credit spreads could widen if proceeds are judged insufficient to stabilize operations; options/FX effects are minimal given microcap/NGM listing and low liquidity.

RISK ASSESSMENT: Tail risks include a failed subscription requiring emergency-directed placements or debt covenant breaches (high-impact, low-probability), or operational/regulatory miscues given the notice correction. Immediate (days) risk: order deletions and liquidity gaps around Jan 2–5; short-term (weeks) risk: share-price dilution and rights-market mispricing through Jan 20; long-term (quarters) risk: capital deployment failure leading to solvency pressure. Hidden dependencies: underwriter commitments, insider participation rates, and use-of-proceeds transparency — these will determine whether dilution is stabilizing or dilutionary without benefit.

TRADE IMPLICATIONS: Direct play — lean short NIUTEC equity (NIUTEC BTA/ordinary) from ex-rights Jan 5 through rights trading end Jan 20 sized 1–2% NAV, target 20–40% downside, stop 15% adverse move. Arb — buy NIUTEC TR (rights) and exercise if TR price < TERP by >10% (TERP = (market cap + new shares*0.25)/post shares); execute Jan 9–20 and hold BTAs to Feb 11. Options — if liquid, buy Mar 2026 put spreads (0.5–1% NAV) to cap premium. Avoid sector reweights; treat as microcap special rather than sector call.

CONTRARIAN ANGLES: Consensus will assume mechanical sell pressure; that misses the possibility of high insider take-up or strategic conversion where >80% subscription would materially repair liquidity and force a sharp rebound. Reaction may be overdone if rights trade at >25% implied discount to TERP — that creates a low-risk exercise arb. Historical parallels: small-cap deep-discount rights often recover post-subscription when proceeds fund clear cash runway; unintended consequence: aggressive shorting could leave a squeeze if insiders/PE take-up exceeds 60–80%.

Key Decisions for Investors

• Establish a tactical short position in NIUTEC ordinary/BTA (ticker NIUTEC on NGM) sized 1–2% NAV between Jan 5 and Jan 23; set take-profit at 20–40% decline and stop-loss at 15% adverse move.
• Execute a capital-efficient rights arb: buy Niutech TR (NIUTEC TR) between Jan 9–20 if rights trade at ≥10% discount to your calculated TERP, exercise and hold BTAs through Feb 11; size 0.5–1% NAV and only exercise when math yields ≥€0.02–0.05/share immediate intrinsic gain (use SEK pricing).
• If exchange-traded options exist, buy Mar 2026 put spreads on NIUTEC sized 0.5–1% NAV to monetize expected post-ex-rights volatility; prefer debit put spreads to limit capital at risk.
• Monitor subscription uptake and underwriter commitments daily from Jan 9–23; if subscription rate >80% or BTA secondary trades above SEK0.40, flip short exposure to a tactical long of 0.5–1% NAV within 5 trading days.